Optimized cocktail of 90Y/177Lu for radionuclide therapy of neuroendocrine tumors of various sizes: a simulation study. Issue 6 (7th March 2022)

• Record Type: Journal Article
• Authors: Peer-Firozjaei, Milad; Tajik-Mansoury, Mohammad Ali; Geramifar, Parham; Ghorbani, Raheb; Zarifi, Shiva; Miller, Cassandra; Rahmim, Arman
• Is Part Of: Nuclear medicine communications. Volume 43:Issue 6(2022)
• Page Start: 646
• Page End: 655
• Publication Date: 2022-03-07
• Subjects: radioisotope cocktail -- tumor dosimetry -- 177Lu, 90Y; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000001546
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : Background and objectives: There is significant interest and potential in the treatment of neuroendocrine tumors via peptide receptor radionuclide therapy (PRRT) using one or both of 90 Y and 177 Lu-labeled peptides. Given the presence of different tumor sizes in patients and differing radionuclide dose delivery properties, the present study aims to use Monte Carlo simulations to estimate S-values to spherical tumors of various sizes with 90 Y and 177 Lu separately and in combination. The goal is to determine ratios of 90 Y to 177 Lu that result in the largest absorbed doses per decay of the radionuclides and the most suitable dose profiles to treat tumors of specific sizes. Material and methods: Particle transfer calculations and simulations were performed using the Monte Carlo GATE simulation software. Spherical tumors of different sizes, ranging from 0.5 to 20 mm in radius, were designed. Activities of 177 Lu and 90 Y, individually and in combination, were homogeneously placed within the total volume of the tumors. We determined the S-values to the tumors, and to the external volume outside of the tumors (cross-dose) which was used to approximate background tissue. The dose profiles were obtained for each of the different tumor sizes, and the uniformity of dose within each tumor was calculated. Results: For all tumor sizes, the self-dose and cross-dose per decay from 90 Y were higher than that from 177 Lu. We observed that 177 Lu had the most uniform dose distribution within tumors with radii less than 5 mm. For tumors greater than 5 mm in radius, a ratio of 25% 90 Y to 75% 177 Lu resulted in the most uniform doses. When the ratio of 177 Lu to 90 Y was smaller, the uniformity improved more with increasing tumor size. The cross-dose stayed approximately constant for tumors larger than 15 mm for all ratios of 177 Lu to 90 Y. Finally, as the size of the tumor increased, differences in the S-values between different ratios of 177 Lu to 90 Y decreased. Conclusion: Our work showed that to achieve a more uniform dose distribution within the tumor, 177 Lu alone is more effective for small tumors. For medium and large tumors, a ratio of 90 Y to 177 Lu with more or less 177 Lu, respectively, is recommended.